BioSpace News Archive

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023.

Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights.

BioStem Technologies Inc. reported financial results for the quarter ended September 30, 2023.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today shared three posters at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® in Boston, MA.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST.

Quest Diagnostics announced that its Board of Directors declared a quarterly cash dividend of $0.71 per share, payable on January 31, 2024 to shareholders of record of Quest Diagnostics common stock on January 17, 2024.

Eyenovia, Inc. announced its financial and operating results for the third quarter ended September 30, 2023.

Rezolute, Inc., a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023.

Avenue Therapeutics, Inc. reported financial results and recent corporate highlights for the third quarter ended September 30, 2023.

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the third quarter ended September 30, 2023.